Production lines equipped with modern manufacturing technology and thorough quality control measures ensure that all of the products meet the high international standards for primary pharmaceutical packaging. Photo: SCHOTT/A. Matjuschetschkin
In addition to strengthening its own domestic pharmaceutical industry, Russia is also trying to convince foreign companies to manufacture inside the country. And, in fact, the Russian government has been able to achieve initial successes in this area. The French pharmaceutical company Sanofi-Aventis took over the existing manufacturing sites of Bioton-Wostok when it acquired this insulin manufacturer. The Swiss company Nycomed built a completely new plant in Yaroslavl, about 300 kilometers north-east of Moscow. The American manufacturer Johnson & Johnson decided to enter the Russian market by way of licensed manufacturing and is having its HIV protease inhibitor manufactured by the Russian manufacturer Pharmstandard.
The British pharmaceutical company GlaxoSmithKline, on the other hand, has chosen to take the route of sharing production. A joint injection production facility is being established together with Binnofarm, a subsidiary of afk-Sistema. The Swiss company Novartis has announced the largest investment thus far. Among other things, the company is planning to invest 500 million dollars in Russia in a manufacturing site for brand generics and pharmaceuticals in Saint Petersburg over the next five years. 1.5 billion units of medications are ex‑ pected to leave the belts in the Special Economic Zone of Novo- Orlovskaya by 2014. Companies like Biokad, Samson-Med, Gerofarm and Farm-Holding are planning to set up operations in the industrial area of “Pushkinskaya” which the city of Saint Petersburg has made available for this specific purpose. As all of these developments show, Russia is seriously interested in internationalizing its pharmaceutical market and has therefore decided to create the right type of climate for investments.
Closer to Russian customers thanks to new pharmaceutical manufacturing facility
These positive trends are also having a similar effect on the packaging market. High-quality primary pharmaceutical packaging made of glass, in particular, is meeting with high demand that is constantly on the rise. SCHOTT Pharmaceutical Packaging elected to establish a production site of its own for ampoules and vials in order to be able to meet this demand even better and more quickly than before. The company decided to open a site in Zavolzhe, a small city located north-west of Nizhny Novgorod. Besides how close it is to Moscow, this region has a solid infrastructure and is already home to many experts. Due to the fact that a SCHOTT production site for flat glass is already located in the region, this opens up opportunities to explore internal synergy effects.
SCHOTT Pharmaceutical Packaging
|Innovation||Products||Press||Careers||SCHOTT North America|